Criteria of immobilization duration of the affected foot in diabetic Charcot neuro-osteoarthropathy

Cover Page


Long-term offloading is the key factor in the treatment of the acute stage of Charcot foot. The indication for remobilization and transition of the affected foot to weight-bearing activities is believed to be based on two factors: the absence of the clinical signs of inflammation and results of the objective diagnostic tests. At the present time, consensus about appropriate methods sufficient for initiating weight-bearing activities after immobilization is absent. This paper discusses current data on clinical and laboratory tests and methods and describes their advantages and disadvantages.

About the authors

Anastasia Gennad'evna Demina

Saint-Petersburg City Diabetes Centre; Federal Almazov Scientific Medical Centre, Saint-Petersburg


Russian Federation

MD, Podiatrist in Saint-Petersburg City Diabetes Centre, research assistant of Diabetology Laboratory in Endocrinology Institute of Federal Almazov Scientific Medical Centre

Vadim Borisovich Bregovskiy

Saint-Petersburg City Diabetes Centre; Federal Almazov Scientific Medical Centre, Saint-Petersburg

Author for correspondence.

Russian Federation MD, PhD, Podiatrist in Saint-Petersburg City Diabetes Centre, leading researcher of Diabetology Laboratory in Endocrinology Institute of Federal Almazov Scientific Medical Centre

Irina Al'bertovna Karpova

Saint-Petersburg City Diabetes Centre


Russian Federation

MD, PhD, Head of Saint-Petersburg City Diabetes Centre


  1. Rogers LC, Frykberg RG, Armstrong DG, Boulton AJM, Edmonds M, Van GH, et al. The Charcot Foot in Diabetes. Diabetes Care 2001;34(9):2123-2129. Available from: doi: 10.2337/dc11-0844.
  2. Sinha S, Munichoodappa CS, Kozak GP. NEURO-ARTHROPATHY (CHARCOT JOINTS) IN DIABETES MELLITUS. Medicine 1972;51(3):191-210. Available from: doi: 10.1097/00005792-197205000-00006.
  3. Cofield RH, Morrison MJ, Beabout JW. Diabetic Neuroarthropathy in the Foot: Patient Characteristics and Patterns of Radiographic Change. Foot & Ankle International 1983;4(1):15-22. Available from: doi: 10.1177/107110078300400104.
  4. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJM. Diabetic Foot Syndrome: Evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003;26(5):1435-1438. Available from: PubMed PMID: 12716801. doi: 10.2337/diacare.26.5.1435.
  5. Chantelau EA, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging--a review of 71 cases. Swiss Med Wkly 2013;143. Available from: PubMed PMID: 23897135. doi: 10.4414/smw.2013.13831.
  6. Sandrow RE, Torg JS, Lapayowker MS, Resnick EJ. The Use of Thermography in the Early Diagnosis of Neuropathic Arthropathy in the Feet of Diabetics. Clinical Orthopaedics and Related Research 1972;88:31-33. Available from: doi: 10.1097/00003086-197210000-00004.
  7. Armstrong DG, Lavery LA. Monitoring healing of acute Charcot's arthropathy with infrared dermal thermometry. J Rehabil Res Dev 1997;34(3):317-321. Available from: PubMed PMID: 9239625.
  8. Armstrong D, Lavery L, Liswood P, Todd W, Tredwell J. Infrared Dermal Thermometry for the High-Risk Diabetic Foot. Phys Ther 1997;77:169-175.
  9. Armstrong D, Lavery L. Acute Charcot's Arthropathy of the Foot and Ankle. Phys Ther 1998;78:74-80.
  10. Котухова ЯВ. Комплексная клинико-лучевая диагностика и медико-социальная реабилитация при диабетической остеоартропатии. Автореф. дис. к.м.н. Обнинск; 2002.
  11. McCrory J, Morag E, Norkitis A, Barr M, Moser R, Caputo G, et al. Ulbrecht J Healing of Charcot fractures: skin temperature and radiographic correlates. The Foot 1998;8:158-165.
  12. Moura-Neto A, Fernandes T, Zantut-Wittmann D, Trevisan R, Sakaki M, Santos A, et al. Charcot foot: skin temperature as a good clinical parameter for predicting disease outcome. Diabetes Res Clin Pract 2012;96:11-14.
  13. Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001;44(11):2032-2037. Available from: PubMed PMID: 11719835. doi: 10.1007/s001250100008.
  14. Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM, Manto A, et al. Six-Month Treatment With Alendronate in Acute Charcot Neuroarthropathy: A randomized controlled trial. Diabetes Care 2005;28(5):1214-1215. Available from: PubMed PMID: 15855594. doi: 10.2337/diacare.28.5.1214.
  15. Ruotolo V, Di Pietro B, Giurato L, Masala S, Meloni M, Schillaci O, et al. A New Natural History of Charcot Foot. Clinical Nuclear Medicine 2013;38(7):506-509. Available from: doi: 10.1097/RLU.0b013e318292eecb.
  16. Eichenholtz S. Charcot Joints. With a foreword by Philip D Wilson. Springfield Illinois: Charles C. Thomas Publisher; 1966.
  17. Classen JN, Rolley RT, Carneiro R, Martire JR. Management of foot conditions of the diabetic patient. Am Surg 1976;42(2):81-88. Available from: PubMed PMID: 1247258.
  18. Schlossbauer T, Mioc T, Sommerey S, Kessler SB, Reiser MF, Pfeifer K. Magnetic resonance imaging in early stage charcot arthropathy: correlation of imaging findings and clinical symptoms. Eur J Med Res 2008;13(9):409-414. Available from: PubMed PMID: 18948232.
  19. Edmonds M, Petrova N, Edmonds A, Elias D. What happens to the initial bone marrow oe-dema in the natural history of Charcot osteoarthropathy? Abstracts of the VIth Meeting of the Diabetic Foot Study Group of the EASD (Elsinore, Denmark, 10-13 Sept. 2006):24.
  20. Zampa V, Bargellini I, Rizzo L, Turini F, Ortori S, Piaggesi A, et al. Role of Dynamic MRI in the follow-up of acute Charcot foot in patients with diabetes mellitus. Skeletal Radiol 2011;40(8):991-999. Available from: doi: 10.1007/s00256-010-1092-0.
  21. Thorning C, Gedroyc WMW, Tyler PA, Dick EA, Hui E, Valabhji J. Midfoot and Hindfoot Bone Marrow Edema Identified By Magnetic Resonance Imaging in Feet of Subjects With Diabetes and Neuropathic Ulceration Is Common but of Unknown Clinical Significance. Diabetes Care 2010;33(7):1602-1603. Available from: PubMed PMID: 20413517. doi: 10.2337/dc10-0037.
  22. Chantelau EA, Grützner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot?. Swiss Med Wkly 2014;144:144-13948. Available from: PubMed PMID: 24764120. doi: 10.4414/smw.2014.13948.
  23. Capriotti G, Chianelli M, Signore A. Nuclear medicine imaging of diabetic foot infection: results of meta-analysis. Nuclear Medicine Communications 2006;27(10):757-764. Available from: doi: 10.1097/01.mnm.0000230065.85705.b3.
  24. Papanas N, Zissimopoulos A, Maltezos E. The role of nuclear medicine in the diagnosis of common and specific diabetic infections. Hell J Nucl Med 2010;13(2):150-157. Available from: PubMed PMID: 20808989.
  25. Larcos G, Brown ML, Sutton RT. Diagnosis of osteomyelitis of the foot in diabetic patients: value of 111In-leukocyte scintigraphy. American Journal of Roentgenology 1991;157(3):527-531. Available from: doi: 10.2214/ajr.157.3.1872240.
  26. Familiari D, Glaudemans AWJM, Vitale V, Prosperi D, Bagni O, Lenza A, et al. Can Sequential 18F-FDG PET/CT Replace WBC Imaging in the Diabetic Foot. Journal of Nuclear Medicine 2001;52(7):1012-1019. Available from: doi: 10.2967/jnumed.110.082222.
  27. Bem R, Jirkovska A, Dubsky M, Fejfarova V, Buncova M, Skibova J, et al. Role of Quantitative Bone Scanning in the Assessment of Bone Turnover in Patients With Charcot Foot. Diabetes Care 2010;33(2):348-349. Available from: doi: 10.2337/dc09-0950.
  28. Pickwell KM, van Kroonenburgh MJ, Weijers RE, van Hirtum PV, Huijberts MS, Schaper NC. F-18 FDG PET/CT Scanning in Charcot Disease. Clinical Nuclear Medicine 2011;36(1):8-10. Available from: PubMed PMID: 21157199. doi: 10.1097/RLU.0b013e3181feeb30.
  29. McGill M, Molyneaux L, Bolton T, Ioannou K, Uren R, Yue DK. Response of Charcot's arthropathy to contact casting: assessment by quantitative techniques. Diabetologia 2000;43(4):481-484. Available from: doi: 10.1007/s001250051332.
  30. Mabilleau G, Petrova N, Edmonds ME, Sabokbar A. Number of circulating CD14-positive cells and the serum levels of TNF-α are raised in acute charcot foot. Diabetes Care;34(3):33. doi: 10.2337/dc10-1695.
  31. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008;51(6):1035-1040. Available from: PubMed PMID: 18389210. doi: 10.1007/s00125-008-0992-1.
  32. Uccioli L, Sinistro A, Almerighi C, Ciaprini C, Cavazza A, Giurato L, et al. Proinflammatory Modulation of the Surface and Cytokine Phenotype of Monocytes in Patients With Acute Charcot Foot. Diabetes Care 2010;33(2):350-355. Available from: PubMed PMID: 19880584. doi: 10.2337/dc09-1141.

Supplementary files

There are no supplementary files to display.



Abstract - 1355

PDF (Russian) - 855




Copyright (c) 2014 Demina A.G., Bregovskiy V.B., Karpova I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies